Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mahamaya LifesciencesBOM:544611 16 Pretax Margin % is 7.52% as of Mar. 2026, which is 71% above its 10-year median of 4.41. GuruFocus rates BOM:544611 with a GF Score™ of 16/100. The stock has 4 warning signs investors should review. Among 248 Agriculture companies, Mahamaya Lifesciences ranks better than 57.26% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Mahamaya Lifesciences Pretax Margin % Related Terms
Mahamaya Lifesciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Mahamaya Lifesciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544611 vs CTVA, CF, MOS: Pretax Margin % Comparison
For the Agricultural Inputs subindustry, Mahamaya Lifesciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mahamaya Lifesciences Pretax Margin % vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Mahamaya Lifesciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Mahamaya Lifesciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mahamaya Lifesciences (BOM:544611) has a Pretax Margin % of 7.52% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mahamaya Lifesciences and its competitors. This is 71% above median its historical median of 4.41. Over the past decade, Mahamaya Lifesciences' Pretax Margin % has ranged from 3.72 to 7.52. According to the industry distribution chart, Mahamaya Lifesciences ranks #106 out of 248 companies in the Agriculture industry, placing it in the top 42.7%.
Is Mahamaya Lifesciences' Pretax Margin % too high?
Mahamaya Lifesciences' current Pretax Margin % of 7.52% is 71% above median its 10-year median of 4.41. Over the past 10 years, this metric has ranged from a low of 3.72 to a high of 7.52. The Agriculture industry median Pretax Margin % is 6.32. Mahamaya Lifesciences' value of 7.52% is 19.1% above this industry median. Based on the distribution chart, Mahamaya Lifesciences ranks #106 out of 248 companies in the Agriculture industry, which is above the industry midpoint. Overall, Mahamaya Lifesciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Mahamaya Lifesciences' Pretax Margin % compare to CTVA and CF?
According to the Agriculture industry distribution chart, Mahamaya Lifesciences ranks #106 out of 248 companies for Pretax Margin %. This puts Mahamaya Lifesciences in the upper half of its industry. The industry median Pretax Margin % is 6.32. Mahamaya Lifesciences' value of 7.52% is 19.1% above this benchmark. Historically, Mahamaya Lifesciences' own Pretax Margin % has ranged from 3.72 to 7.52 over the past decade. While the company's 10-year median is 4.41 vs. the industry median of 6.32, Mahamaya Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for an Agriculture company?
The median Pretax Margin % among Agriculture companies is 6.32, based on 248 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mahamaya Lifesciences's current Pretax Margin % of 7.52% is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mahamaya Lifesciences and its competitors. For the Agriculture industry, the median Pretax Margin % is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mahamaya Lifesciences's current Pretax Margin % is 7.52%, which is 71% above median its own 10-year median of 4.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mahamaya Lifesciences stock overvalued right now?
Mahamaya Lifesciences (BOM:544611) has a current Pretax Margin % of 7.52%. The current Pretax Margin % is 7.52%, which is 71% above median its 10-year median of 4.41 and 19.1% above the Agriculture industry median of 6.32. Mahamaya Lifesciences' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Mahamaya Lifesciences (BOM:544611), the current Pretax Margin % is 7.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mahamaya Lifesciences Ltd specializes in the manufacturing of pesticide formulations and supplies bulk formulations catering to both Indian agrochemical companies as well as multinational corporations (MNCs). The company's offerings include Insecticides, Herbicides, and Fungicides. Geographically, it serves multiple Indian states including Punjab, Haryana, Rajasthan, and Uttar Pradesh, and internationally serves countries like the Dominican Republic, Turkey, Egypt, and the UAE. The company generates revenue from the sale of its pesticide formulations.
16GF Score
Get the complete analysis for BOM:544611
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544611 has been successfully added to your 
